Bristol Myers Squibb Company’s plan to battle back against coming losses of exclusivity (LOE) for its three top-selling products throughout this decade is going largely to plan, according to chief commercialization officer Chris Boerner. The fight against generic and biosimilar competitors for Revlimid, Opdivo and Eliquis will be won through strong commercial execution for Opdualag, Camzyos, Sotyktu – all approved in the US in 2022 – and six other recent product launches.
During the past three years, Boerner’s commercial teams have brought nine new drugs to market that BMS expects to generate...
